DexCom, Inc. (DXCM) EVP Sells $100,731.50 in Stock
DexCom, Inc. (NASDAQ:DXCM) EVP Steven Robert Pacelli sold 1,450 shares of the company’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $69.47, for a total transaction of $100,731.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Steven Robert Pacelli also recently made the following trade(s):
- On Friday, June 23rd, Steven Robert Pacelli sold 1,450 shares of DexCom stock. The shares were sold at an average price of $78.19, for a total transaction of $113,375.50.
DexCom, Inc. (DXCM) traded up 0.42% during midday trading on Tuesday, reaching $70.00. 1,434,237 shares of the company’s stock traded hands. DexCom, Inc. has a one year low of $57.68 and a one year high of $96.38. The stock’s 50 day moving average price is $72.86 and its 200-day moving average price is $75.75. The stock’s market cap is $6.05 billion.
DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.55) by $0.06. The business had revenue of $142.30 million during the quarter, compared to the consensus estimate of $143.94 million. DexCom had a negative return on equity of 32.94% and a negative net margin of 14.70%. Equities analysts predict that DexCom, Inc. will post ($0.73) earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: “DexCom, Inc. (DXCM) EVP Sells $100,731.50 in Stock” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/07/25/dexcom-inc-dxcm-evp-sells-100731-50-in-stock.html.
Several equities analysts recently weighed in on the stock. B. Riley restated a “buy” rating and set a $95.00 price target on shares of DexCom in a research report on Tuesday, May 2nd. William Blair restated an “outperform” rating on shares of DexCom in a research report on Thursday, April 27th. Jefferies Group LLC reduced their price target on shares of DexCom to $91.00 and set a “buy” rating for the company in a research report on Tuesday, May 9th. Piper Jaffray Companies restated a “buy” rating and set a $78.00 price target on shares of DexCom in a research report on Wednesday, July 12th. Finally, Canaccord Genuity reduced their price target on shares of DexCom from $95.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $89.47.
Large investors have recently added to or reduced their stakes in the stock. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in DexCom during the first quarter worth about $136,000. IFP Advisors Inc increased its stake in DexCom by 9.3% in the first quarter. IFP Advisors Inc now owns 1,863 shares of the medical device company’s stock worth $158,000 after buying an additional 159 shares in the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in DexCom during the first quarter worth about $164,000. Mn Services Vermogensbeheer B.V. increased its stake in DexCom by 3.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,254 shares of the medical device company’s stock worth $179,000 after buying an additional 83 shares in the last quarter. Finally, Independent Portfolio Consultants Inc. increased its stake in DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after buying an additional 9 shares in the last quarter.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.